Regulatory Updates

Latest News

Verastem Begins Submission for Ovarian Cancer Combination

May 24th 2024

Verastem is studying the combination of avutometinib and defactinib to treat low-grade serous ovarian cancer in patients with KRAS-mutations. The company plans to complete the new drug application in the second half of this year.

 Ольга Тернавская
Updated: FDA Approves First Interchangeable Biosimilars to Eylea

May 21st 2024
Atara Submits BLA for Cell Therapy for Post-Transplant Complication

May 20th 2024
FDA Approves Bispecific Antibody for Small Cell Lung Cancer

May 17th 2024

FDA Approves Breyanzi for Follicular Lymphoma
FDA Approves Breyanzi for Follicular Lymphoma

May 16th 2024

Latest CME Events & Activities

More News

© 2024 MJH Life Sciences

All rights reserved.